Neurosteroids potentiate GABAA receptors that benzodiazepines cannot. Our lead compound, NCT-10003, should have decreased CNS side effects relative to other neurosteroids because it is subtype selective. We also expect this compound will have better pharmacokinetics, resulting in lower doses than competitor drug candidates. This compound demonstrates anxiolytic effects in rodents, and we are currently evaluating it as an anti-epileptic.